HCW Biologics (NASDAQ:HCWB) Shares Up 4.3%

HCW Biologics Inc. (NASDAQ:HCWB) traded up 4.3% on Wednesday . The company traded as high as $0.49 and last traded at $0.49. 7,151 shares were traded during trading, a decline of 57% from the average session volume of 16,466 shares. The stock had previously closed at $0.47.

HCW Biologics Stock Up 4.3 %

The business has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $1.10. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.46 and a current ratio of 0.46. The firm has a market capitalization of $18.53 million, a price-to-earnings ratio of -0.64 and a beta of 0.81.

Institutional Investors Weigh In On HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Avantax Planning Partners Inc. bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 179,541 shares of the company’s stock, valued at approximately $220,000. Avantax Planning Partners Inc. owned about 0.50% of HCW Biologics at the end of the most recent reporting period. 2.96% of the stock is owned by hedge funds and other institutional investors.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.